170861-63-9
Product Name:
4-[[4-[2-(5-methyl-2-phenyl-1,3-oxazol-4-yl)ethoxy]phenyl]methyl]isoxazolidine-3,5-dione
Formula:
C22H20N2O5
Inquiry
COMPUTED DESCRIPTORS
| Molecular Weight | 392.4 g/mol |
|---|---|
| XLogP3 | 4 |
| Hydrogen Bond Donor Count | 1 |
| Hydrogen Bond Acceptor Count | 6 |
| Rotatable Bond Count | 7 |
| Exact Mass | 392.13722174 g/mol |
| Monoisotopic Mass | 392.13722174 g/mol |
| Topological Polar Surface Area | 90.7 Ų |
| Heavy Atom Count | 29 |
| Formal Charge | 0 |
| Complexity | 572 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 0 |
| Undefined Atom Stereocenter Count | 1 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently-Bonded Unit Count | 1 |
| Compound Is Canonicalized | Yes |
PRODUCT INTRODUCTION
description
Reglitazar, an isoxazolidine-3,5-dione derivative, is being developed by Pfizer for the treatment of diabetes. It is the first non-thiazolidenedione to enter clinical trials.